ArtBlood Aims to Manufacture Blood in Factories(venturesquare.net)
Writing language: KoreanRead in the original language
Plain summary
- ArtBlood, developing ex-vivo red blood cell production technology, has been selected for the '2026 Supergap Startup Project.'
- Funding to continue research is welcome, but the key issue is whether the blood can be reliably mass-produced at hospital-grade quality.
- In biotech startups, attention focuses more on how far the costly verification during clinical and production stages can be completed than on the total amount of grants.
Have you run into something like this? Tell us in a line or two what you did. You do not need to know the product.